Product Images Desvenlafaxine

This is a description of a medicine labeled as "SEALED FOR YOUR PROTECTION". The tablets contain 100 mg of desvenlafaxine and are intended for extended release. The recommended dosage and manufacturer details are given alongside storage instructions of keeping the tablets between 20°C to 25°C. These tablets should be dispensed with a medication guide for each patient. The batch number is B0, and the medicine is intended to be dispensed by a licensed pharmacist.*

The text describes a figure (Figure 1) showing the impact of other drugs on the pharmacokinetics (PK) of Desvenlafaxine. The figure includes recommendations for adjusting dosage based on the fold change and 90% CI values for different inhibitors of the CYP3A4 enzyme. For example, the Cmax value for Desvenlafaxine is reduced by 4 when administered with Ketoconazole, but no dose adjustment is recommended. The text does not provide enough information to understand the full context or purpose of the figure.*

This is a table (Figure 2) that shows the impact of Desvenlafaxine on the pharmacokinetics of three drugs, namely Desipramine, Midazolam, Tamoxifen, and Aripiprazole. The table shows the change in pharmacokinetics due to the interaction of Desvenlafaxine with these drugs. It also provides recommendations on dose adjustment for each drug based on the changes observed in pharmacokinetics.*

This is a table presenting the impact of intrinsic factors such as renal impairment, hepatic impairment, and population description on PK parameters (Cmax, AUC) regarding an unspecified drug. Each intrinsic factor has different categories such as mild, moderate, severe, and end-stage renal disease (ESRD). The population description includes age and gender categories. The table shows the fold change and 90% CI recommendation for dosing adjustments or no adjustment. However, there is not enough information to provide specific recommendations since the drug and the PK parameters are undefined.*

This is a pharmaceutical label for Desvenlafaxine extended-release tablets containing 50 mg of medication per tablet. It includes information on dosage and storage, as well as the manufacturing company Alembic Pharmaceuticals Limited located in Gujarat, India. The NDC code, lot number, and license for the medication are also provided. A medication guide should be provided to each patient along with the 30-tablet prescription.*